¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"phase test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
¿µ¹® blood test ÇÑ±Û Ç÷¾×°Ë»ç
¼³¸í   
  Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇϴ °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é À̵頼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • menstrual phase
    ¿ù°æ±â
  • negative phase
    1. À½¼º»ó 2. Ç×ü°¨¼Ò±â
  • oral phase
    ±¸°­±â
  • orgasmic phase
    ¼º±ØÄ¡±â
  • ovogenetic phase
    ³­Àڹ߻ý±â
  • phase difference
    À§»óÂ÷
  • phase display
    À§»óÇ¥½Ã
  • phase encoding gradient
    À§»óºÎȣȭ±â¿ï±â
  • phase encoding step
    À§»óºÎȣȭ´Ü°è
  • phase image
    À§»ó¿µ»ó
  • phase offset multiplanar imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • phase ratio
    »óºñ
  • phase reversal
    À§»ó¹ÝÀü
  • phase rule
    »óÀǹýÄ¢, »ó±ÔÄ¢
  • phase shift
    À§»óº¯À§, À§»óÀ̵¿
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • inhibition test
    ¾ïÁ¦°Ë»ç
  • intelligence test
    Áö´É°Ë»ç
  • intradermal test
    Çdz»°Ë»ç, Çdz»¹ÝÀÀ°Ë»ç
  • metacholine challenge test
    ¸ÞŸÄݸ°À¯¹ß°Ë»ç
  • NBT test
    (¢¡nitroblue tetrazolium test) ´ÏÆ®·Îºí·çÅׯ®¶óÁ¹·ý°Ë»ç
  • nonstress test
    ºñ¼öÃà°Ë»ç
  • occlusion test
    1.¸Â¹°¸²°Ë»ç, ±³ÇÕ°Ë»ç, 2.Æó¼â°Ë»ç
  • occult blood test
    ÀáÇ÷°Ë»ç
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´çºÎÇϰ˻ç
  • osmotic fragility test
    »ïÅõ¾ÐÃë¾à¼º°Ë»ç, »ïÅõ¾Ð¿©¸²¼º°Ë»ç
  • Pap test
    (¢¡Papanicolaou test) ÆÄÆÄ´ÏÄݷΰ˻ç
  • Papanicolaou test
    ÆÄÆÄ´ÏÄݷΰ˻ç
  • patch test
    ÇǺÎÁ¢Ã˰˻ç, øÆ÷°Ë»ç
  • paternity test
    Ä£ÀÚ°¨Á¤
  • pilot test
    ¿¹ºñ°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • in-phase image
    À§»ó³»¿µ»ó
  • inflow phase
    À¯ÀÔ±â
  • inspiratory phase
    Èí±â»ó
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • internal phase
    ³»»ó
  • intuitive phase
    Á÷°ü±â
  • involutional phase
    ÅðÈ­±â
  • isometric contraction phase
    µîô¼º¼öÃà±â
  • isovolumetric contraction phase
    µî¿ëÀû¼º¼öÃà±â
  • phase image
    À§»ó¿µ»ó
  • phase offset multiplannar imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • lactiferous phase
    ¼öÀ¯±â
  • leptotene phase
    °¡´Â¼¶À¯±â
  • logarithmic phase
    ´ë¼öÁõ½Ä±â
  • luteal phase
    Ȳü±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • phase angle
    À§»ó °¢
  • phase artifact
    À§»ó Àΰø¹°
  • phase axis
    ˤȗ ̈
  • phase boundary
    »ó°è(Ë×Ë­).
  • phase boundary force
    »ó°è(Àü)·Â(ßÓÍ£ ï³æ³).
  • phase boundary potential
    »ó°èÀüÀ§(ßÓÍ£ ï³êÈ).
  • phase coherence
    À§»ó °áÁý
  • phase conjugate symmetry
    À§»ó ȸº¹ ´ëĪ (À§»ó °ø¾× ´ëĪ)
  • phase constant
    À§»ó»ó¼ö(êÈßÓßÈâ¦).
  • phase contrast
    À§»ó ´ëÁ¶
  • phase contrast (PC) MR angiography
    À§»ó ´ëÁ¶ ÀÚ±â°ø¸í Ç÷°üÁ¶¿µ¼ú
  • phase contrast microscopy
    À§»óÂ÷(êÈßÓó¬)Çö¹Ì°æ°Ë»ç
  • phase curve
    À§»ó °î¼±
  • phase delay
    »óÁö¿¬(ßÓòÀæÅ)
  • phase difference
    À§»óÂ÷(êÈßÓó¬).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • estrogen phase
    ¿¡½ºÆ®·Î°Õ±â(Ñ¢).
  • estrogen phase
    ¿¡½ºÆ®·Î°Õ±â.
  • excitement phase
    ÈïºÐ±â
  • expiratory phase
    È£½Ä»ó(û¼ãÓßÓ).
  • expiratory phase time
    È£±â»ó ½Ã°£.
  • explosive phase
    Æø¹ß±â(̰ËÑË»).
  • exponential growth phase
    Áö¼öÁõ½Ä±â(ÊÙÌ¡ËàË»).
  • exponential phase
    ´ë¼öÁõ½Ä±â, Áö¼öÁõ½Ä±â
  • exponential phase of growth
    ´ë¼öÁõ½Ä±â, °¡¼Ó¼ºÀå±â.
  • filling phase
    Ãæ¸¸±â(õöػѢ).
  • flagellar phase variation
    Æí¸ðÀ§»óº¯ÀÌ
  • follicle phase
    ³­Æ÷±â(Õ°øàÑ¢).
  • follicular phase
    ³­Æ÷±â(Õ°øàÑ¢).
  • follicular phase
    ³­Æ÷±â
  • full erection phase
    ¿ÏÀü¹ß±â±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • benzidine test
    º¥Áöµò½ÃÇè(ãËúÐ)
  • blind test
    ¸Í°Ë(ØîËþ)
  • Bradshaw test
    ºê·¡µå¼î¿ì ½ÃÇè(ãËúÐ)
  • capon test
    °Å¼¼(ËÛá§)´ß ½ÃÇè(ãËúÐ)
  • carbohydrate tolerance test
    ´çÁú ºÎÇϽÃÇè(ÓØòõݶùÃãËúÐ)
  • carbon clearance test
    ź¼Ò ûÁ¤½ÃÇè(÷©áÈôèïäãËúÐ)
  • cephalin-cholesterol flocculation test
    ¼¼ÆÈ¸°-ÄÝ·¹½ºÅ×·Ñ ¸é»ó½ÃÇè(ØúßÒãËúÐ)
  • chronic toxicity test
    ¸¸¼º µ¶¼º½ÃÇè(Ø·àõÔ¸àõãËúÐ)
  • cis-trans test
    ½Ã½ºÆ®¶õ½º ½ÃÇè(ãËúÐ)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
  • complementation test
    »óº¸½ÃÇè(ßÓÜÍãËúÐ)
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • complement fixation test
    º¸Ã¼°íÁ¤½ÃÇè(ÜÍô÷ͳïÒãËúÐ)
  • consumption test
    ¼Ò¸ð½ÃÇè(á¼ÙÄãËúÐ)
  • Coombs' test
    ÄñÁî ½ÃÇè(ãËúÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • phase cancellation artifact
    À§»ó¸»¼Ò(»ó¼â)Àΰø¹°
  • phase coherence
    À§»ó°áÁý
  • phase conjugate symmetry
    À§»óȸº¹´ëĪ, À§»ó°ø¾×´ëĪ
  • phase contrast
    À§»ó´ëÁ¶
  • phase contrast MR angiography
    À§»ó´ëÁ¶ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • phase curve
    À§»ó°î¼±
  • phase display
    À§»óÇ¥½Ã
  • phase encode direction
    À§»óºÎȣȭ¹æÇâ
  • phase encoding
    À§»óºÎȣȭ
  • phase encoding gradient
    À§»óºÎȣȭ°æ»çµµ(Àå)
  • phase encoding step
    À§»óºÎÈ£´Ü°è
  • phase evolution of fat suppression
    À§»ó¼±È¸ Áö¹æ¾ïÁ¦
  • phase frequency swap
    À§»óÁ֯ļö±³È¯
  • phase image
    À§»ó¿µ»ó
  • phase mismapping
    À§»ó¿ÀÁöµµÀÛ¼º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AST allergy serum transfer; angiotensin sensitivity test; anterior spinothalamic tract; antistreptolysin...
CPT carnitine palmityl transferase; carotid pulse tracing; chest physiotherapy; child protection team; c...
CST cardiac stress test; cavernous sinus thrombosis; certified surgical technologist; chemostatin; Chris...
ETT endotracheal tube; epinephrine tolerance test; exercise tolerance test; exercise treadmill test; ext...
MIT Massachusetts Institute of Technology; male impotence test; marrow iron turnover; melodic intonation...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
LLPDD Late Luteal Phase Dysphoric Disorder
LPR Late phase response
LPD Luteal phase defect
LPD Luteal phase deficiency
MPF M phase promoting factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prefunctional eruptive phase
    ±â´ÉÀü ¸ÍÃ⠴ܰè
  • premenstrual :

    premenstrual phase

    ¿ù°æ Àü±â
    ¿ù°æÀÌ °³½ÃÇÏ´Â Á÷Àü ½Ã±â.
  • prodromal vasoconstriction phase
    Àü±¸¼º Ç÷°ü ¼öÃà±â
  • proliferation phase
    Áõ½Ä±â
  • respiratory ordered phase encoding
    È£Èí ¼øÀ§ »ó ºÎȣȭ
  • rising phase
    »ó½Â±â
  • S phase
    S ±â
    Á¤Áö±â, °íÁ¤»ó. ¼¼±Õ ¹è¾ç¿¡ À־ ¼¼±ÕÀÇ Áõ½ÄÀÌ ¼­¼­È÷ ÁÙ¾îµé¾î ¼¼±Õ ¼ö°¡ °ÅÀÇ ÀÏÁ¤ÇÑ ¼ö·Î º¸ÀüµÇ´Â ½Ã±â.
  • sleep phase advance
    ¼ö¸é À§»ó ÀüÁø
  • spin phase effect
    ½ºÇÉ À§»ó È¿°ú
  • stationary phase of growth
    Áõ½Ä Á¤Áö±â
  • symbiotic phase
    °ø»ý±â
  • two-phase color reaction
    µÎ °¡Áö »ö±ò ¹ÝÀÀ
  • unequal phase
    ºñ´ëαâ
  • yeast phase
    È¿¸ð»ó
  • abrasion test
    ¸¶¸ê ½ÃÇè
    ¸¶¸ð¿¡ °ßµð´Â Á¤µµ¸¦ ½ÃÇèÇÏ´Â °Ë»ç.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
M phase Mitotic phase of cell cycle of eukaryotic cells, as distinct from the remainder, which is known as interphase (and that can be further subdivided as G1, s and G2). Beginning of M is signalled by separation of centrioles, where present and by the condensation of chromatin into chromosomes. M phase ends with the establishment of nuclear membranes around the two daughter nuclei, normally followed immediately by cell division (cytokinesis).
(18 Nov 1997)
M phase promoting factor Protein whose levels rise rapidly just before and fall away just after, mitosis. Thought to be a trigger for mitosis.
(18 Nov 1997)
plateau phase <oncology> Stable stage of disease in multiple myeloma following good response to anti-cancer treatment.
(31 Dec 1997)
continuous phase The medium or fluid in which a disperse is suspended.
Synonym: continuous phase, dispersion medium, dispersion phase, external medium.
(05 Mar 2000)
coupling phase The physical relationship of two syntenic genes. If they are on the same chromosome, they are said to be "in coupling" or "in the cis phase"; if on opposite members of a chromosome pair, "in repulsion" or "in the trans phase."
(05 Mar 2000)
positive phase The period following the negative phase, during which the opsonic index rises.
(05 Mar 2000)
postimplantation phase The time period between implantation and placentation.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • pregnancy test
    ÀӽŠ°Ë»ç
  • projective test
    Åõ¿µ °Ë»ç¹ý(µµÇü µî¿¡ ÀÇÇÑ ¼º°Ý Å×½ºÆ®ÀÇ ÀÏÁ¾)
  • road test
    (»õÂ÷ÀÇ)³ë»ó ¼º´É ½ÃÇè;(¿îÀü¸éÇã ÃëµæÀ» À§ÇÑ)³ë»ó ½Ç±â ½ÃÇè;³ë»ó ¼º´É(½Ç±â)½ÃÇèÇÏ´Ù
  • scratch test
    ÇǺΠ¹ÝÀÀ ½ÃÇè
  • screen test
    ¿µÈ­ ¹è¿ìÀÇ Àû¼º(¹è¿ª) ½É»ç
  • skin test
    ÇǺΠ½ÃÇè
  • test
    Å×½ºÆ®;°Ë»ç;½ÃÇè(put to the ~ ½ÃÇèÇÏ´Ù);½ÃÇè¹°;½Ã¾à;½Ã±Ý¼®;stand the ~ ÇÕ°ÝÇÏ´Ù;½ÃÇè¿¡ °ßµð´Ù
  • test
    °Ë»ç(½ÃÇè)ÇÏ´Ù
  • test ban
    ÇÙ½ÇÇè ±ÝÁö ÇùÁ¤
  • test bed
    (Ç×°ø±â ¿£Áø µîÀÇ) ½ÃÇè´ë
  • test case
    Å×½ºÆ®ÄÉÀ̽º;ù½Ãµµ;½Ã¼Ò
  • test paper
    ½ÃÇèÁö
  • test patten
    ½ÃÇè ¹æ¼Û¿ë µµÇü
  • test pilot
    (½ÅÁ¶±âÀÇ) ½ÃÇè Á¶Á¤»ç
  • test tube
    ½ÃÇè°ü
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á